This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Merck Sharp & Dohme LLC. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Michael Lowinger and Pharmaceutical Formulation Innovation.
Introduction
Michael Lowinger is an inventor associated with Ridgewood, New Jersey, and Merck Sharp & Dohme LLC. His patent work includes a pharmaceutical formulation involving suvorexant, an orexin receptor antagonist.
Latest Patents
Lowinger is credited with 1 patent: “Solid Dosage Formulations of an Orexin Receptor Antagonist.” The invention describes a pharmaceutical composition containing suvorexant, or a pharmaceutically acceptable salt of the compound, together with a concentration-enhancing polymer and, optionally, a pharmaceutically acceptable surfactant.
Career Highlights
The patent reflects work on solid dosage formulations designed to incorporate suvorexant and formulation components that can enhance its concentration. Lowinger’s listed company affiliation is Merck Sharp & Dohme LLC.
Collaborations
The supplied information identifies Paul A. Harmon and Narayan Variankaval as coworkers. Their names are associated here as colleagues, without implying a specific role in the patent.
Conclusion
Michael Lowinger’s recorded patent highlights his contribution to pharmaceutical formulation innovation through a solid dosage composition involving suvorexant.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile